Results 21 to 30 of about 4,076 (204)

SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis

Science Translational Medicine
Gray matter pathology, including the formation of cortical lesions, predicts progression in people with multiple sclerosis (PwMS). Here, we investigated whether positron emission tomography (PET) imaging using the synaptic vesicle protein 2A (SV2A)–targeting radioligand [ 18 F]UCB-H could help to detect and monitor ...
Ullrich Gavilanes, Emily M, Bartos, Laura M, Gernert, Jonathan A, Carral, Carla Ares, Ruiz Navarro, Diego, Havla, Joachim, Gerdes, Lisa-Ann, Gnörich, Johannes S, Kunze, Lea H, Dorneich, Julia S, Pakula, Vanessa, Tagnin, Lisa, Zimmermann, Hanna, Seelos, Klaus, Franzmeier, Nicolai, Frontzkowski, Lukas, Pedrosa de Barros, Nuno, Ribbens, Annemie, Zwergal, Rachel Maria, Zwergal, Andreas, Vollmar, Christian, Remi, Jan, Picon Munoz, Carmen, Reynolds, Richard, Merkler, Doron, Wattjes, Mike P, Kümpfel, Tania, Brendel, Matthias, Kerschensteiner, Martin   +28 more
openaire   +6 more sources

Role of the SV2A protein in epilepsy and Alzheimer's mouse models

, 2016
SV2s family proteins are neuronal vesicles membrane glycoproteins that are highly conserved in evolution (Janz & Südhof, 1999). It is known that SV2A isoform is the target to Levetiracetam (LEV), an effective anti-epileptic drug (B. Lynch et al., 2004). There are certain hypotheses about his role in epilepsy. However, his physiological function and its
Sánchez Gil, Judit
core   +3 more sources

Targeting SV2A for discovery of antiepileptic drugs [PDF]

Epilepsia, 2010
SummaryLevetiracetam’s (Keppra) binding site and its subsequent identification as the synaptic vesicle protein 2A (SV2A) enabled the discovery of high affinity SV2A ligands with promising anticonvulsant properties. Among these, brivaracetam was selected for further development.
Rafal M. Kaminski, Michel Gillard, Henrik Klitgaard   +2 more
openaire   +1 more source

The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment

Frontiers in Cell and Developmental Biology, 2021
Alzheimer’s disease (AD), a serious neurodegenerative disease, is pathologically characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an indispensable vesicular protein specifically expressed in synapses and can be used ...
Yanyan Kong, Lin Huang, Weihao Li, Xuanting Liu, Yinping Zhou, Cuiping Liu, Shibo Zhang, Fang Xie, Zhengwei Zhang, Donglang Jiang, Weiyan Zhou, Ruiqing Ni, Chencheng Zhang, Bomin Sun, Jiao Wang, Yihui Guan   +15 more
doaj   +1 more source

PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging

Frontiers in Neuroscience, 2022
The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga, Arman Fesharaki-Zadeh, Arman Fesharaki-Zadeh, Stephen M. Strittmatter, Stephen M. Strittmatter, Richard E. Carson, Zhengxin Cai   +6 more
doaj   +1 more source

Novel Brain Synaptic Density Nuclide Molecular Probe 18F-SynVesT-1 Radiolabeling, Quality Control and Imaging Analysis

Journal of Isotopes, 2023
Neural synapses were the fundamental sites of interneuronal connections and the structural basis for information transmission in brain networks, and alterations in synapse density were closely related to a variety of nervous system disorders.
HU Zhengquan;XIANG Shijun;TANG Yongxiang;CHEN Dengming;HU Shuo
doaj   +1 more source

Ligan SV2A sebagai Terapi Epilepsi

Jurnal Farmasi Udayana, 2020
Epilepsi menggambarkan suatu kondisi di mana seseorang memiliki risiko kejang berulang karena proses kronik yang mendasarinya. Seizure (kejang) adalah tanda-tanda atau gejala-gejala sementara yang disebabkan oleh aktifitas neuronal otak yang berlebihan. Kejang  terjadi karena terjadi ketidakseimbangan eksitasi dan inhibisi dalam CNS.
Sumarno Sumarno, Lindae Novianae
openaire   +2 more sources

SV2A in Epilepsy: The Plot Thickens [PDF]

Epilepsy Currents, 2010
Decreased Expression of Synaptic Vesicle Protein 2A, the Binding Site for Levetiracetam, during Epileptogenesis and Chronic Epilepsy. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. Epilepsia 2009;50(3):422–433. PURPOSE: We previously showed that gene expression of synaptic vesicle protein 2A (SV2A), the binding site for the antiepileptic drug ...
openaire   +2 more sources

SV2A is expressed in synapse subpopulations in mouse and human brain: implications for PET radiotracer studies [PDF]

Synapse pathology is a feature of most brain diseases and there is a pressing need to monitor the onset and progression of this pathology using brain imaging in living patients.
Tavares, Adriana, Grant, Seth G.N., Qiu, Zhen; id_orcid, Smith, Colin, Notman, Beverly, Wong, Theresa   +5 more
core   +5 more sources

A single dose of cocaine raises SV2A density in hippocampus of adolescent rats [PDF]

Acta Neuropsychiatrica, 2023
AbstractObjectiveCocaine is a highly addictive psychostimulant that affects synaptic activity with structural and functional adaptations of neurons. The transmembrane synaptic vesicle glycoprotein 2A (SV2A) of pre-synaptic vesicles is commonly used to measure synaptic density, as a novel approach to the detection of synaptic changes.
Rachele Rossi, Simone Larsen Bærentzen, Majken B. Thomsen, Caroline C. Real, Gregers Wegener, Rodrigo Grassi-Oliveira, Albert Gjedde, Anne M. Landau   +7 more
openaire   +4 more sources